Galapagos' filgotinib meets Phase II endpoint in RA

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said Janus kinase-1 (JAK-1) inhibitor filgotinib ( GLPG0634) met the primary endpoint vs. placebo of the Phase IIb DARWIN 1 trial to treat rheumatoid arthritis (RA). Galapagos expects to reports full results from the 24-week trial mid-year.

Filgotinib plus methotrexate led to a statistically significant improvement in American College of Rheumatology 20 (ARC20) scores at 12 weeks vs. placebo plus methotrexate. ...